Diagnosis and Trial Options in Sarcoma

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

Amplification of murine double minute 2 represents a promising target to access the so-called cellular gatekeeper p53 protein in human cancers.

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.

Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.

Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.